Advertisement
Mendus receives final grant payment

Mendus will receive 1.69 million EUR as the final grant payment from the Horizon 2020-funded AML-VACCiN project.
All requirements for the final tranche have been fulfilled, bringing the total financial contribution from the European Commission to 6.0 million EUR for the project as a whole. As a result of the project completion, Mendus is now entitled to receive its final payment under the project.
“The Horizon 2020 AML-VACCiN project has significantly strengthened the European network and the development of expertise supporting the clinical development of DCP-001 as a novel immunotherapy for the treatment of acute myeloid leukemia (AML).”
“The Horizon 2020 AML-VACCiN project has significantly strengthened the European network and the development of expertise supporting the clinical development of DCP-001 as a novel immunotherapy for the treatment of acute myeloid leukemia (AML),” commented Erik Manting, Chief Executive Officer of Mendus. “The ongoing ADVANCE II trial is a direct result of this high-quality consortium and will continue to deliver data, with a comprehensive survival data update expected in December 2022. We are thankful to all the contributors and Stichting VUmc as the coordinator of AML-VACCiN.”
The AML-VACCiN project was initiated in January 2016 and involved more than 10 industry and academic partners from several European countries.
Photo of Erik Manting: Mendus
Published: October 13, 2022
Advertisement